Krystal Biotech, Inc.
KRYSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeKrystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United. The company carries a $10.60B market cap, placing it firmly in the large-cap category. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Market Cap
$10.60B
Beta
0.54
P/E (TTM)
44.84
P/E (Fwd)
38.12
EPS (TTM)
$7.99
EPS (Fwd)
$9.40
ROE
20.1%
ROA
9.4%
Cash
$845.6M
Total Debt
$8.9M
Free CF
$151.7M
52W Change
153.7%
Annual Financials
Cash vs Debt
Where KRYS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, KRYS finished 21.69% above its 150-day moving average ($303.41) and 27.87% above its 200-day moving average ($288.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KRYS overbought or oversold?
At the September 3, 2026 close, KRYS's RSI(14) was 73.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $845.6M in cash and $8.9M in debt, KRYS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $151.7M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 20.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 9.4% suggests reasonable efficiency in deploying the company's asset base.
With a beta below 0.7, Krystal Biotech, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Krystal Biotech, Inc. and its sector.